Should the health community promote smokeless tobacco (snus) as a harm reduction measure? by Gartner, C. E. et al.
PLoS Medicine  |  www.plosmedicine.org 0001
The PLoS Medicine Debate
July 2007  |  Volume 4  |  Issue 7  |  e185
Background to the debate: The tobacco control community is divided on whether or not to inform the 
public that using oral, smokeless tobacco (Swedish snus) is 
less hazardous to health than smoking tobacco. Proponents 
of “harm reduction” point to the Swedish experience. Snus 
seems to be widely used as an alternative to cigarettes in 
Sweden, say these proponents, contributing to the low 
overall prevalence of smoking and smoking-related disease. 
Harm reduction proponents thus argue that the health 
community should actively inform inveterate cigarette 
smokers of the benefi ts of switching to snus. However, 
critics of harm reduction say that snus has its own risks, 
that no form of tobacco should ever be promoted, and 
that Sweden’s experience is likely to be specifi c to that 
culture and not transferable to other settings. Critics also 
remain deeply suspicious that the tobacco industry will 
use snus marketing as a “gateway” to promote cigarettes. 
In the interests of promoting debate, the authors (who are 
collaborators on a research project on the future of tobacco 
control) have agreed to outline the strongest arguments 
for and against promoting Swedish snus as a form of harm 
reduction.
Coral Gartner and Wayne Hall’s Viewpoint: 
Smokers Who Switch to Snus Reduce Their 
Health Risks
Over the past 40 years, high taxes on cigarettes, advertising 
bans, and restrictions on smoking have almost halved adult 
rates of cigarette smoking in Australia and the United 
States [1,2]. Nonetheless, around one in fi ve adults in these 
countries still smokes tobacco because they are either unable 
or unwilling to stop.
We think it would be good public health policy to 
encourage inveterate smokers to adopt less harmful ways 
of using nicotine, to reduce the disease burden caused by 
tobacco smoking [3,4]. This policy—labelled tobacco harm 
reduction (THR)—has prompted heated debate within the 
tobacco control community.
Critics of THR point to the failure of “light” cigarettes to 
reduce health risks because of compensatory smoking (e.g., 
blocking ventilation holes, inhaling more intensely, smoking 
each cigarette down to a smaller butt length, and smoking 
a greater number of cigarettes). Similar strong doubts 
surround the safety of any new combustible tobacco products, 
given that it takes 40 to 50 years to evaluate their potential 
harms or benefi ts [3].
Low nitrosamine oral snuff, or Swedish snus, is not 
vulnerable to the criticisms levelled at light cigarettes. 
Snus has been used by substantial proportions of nicotine 
consumers in Sweden over the past several decades, which has 
allowed its effects on smoking prevalence and health to be 
studied.
Similar to other types of smokeless tobacco products, 
snus may increase the risk of some cancers [5,6,7], and 
there may be some risk of cardiovascular disease caused 
by nicotine. But its cardiovascular risks are certainly lower 
than those of smoking, it has no respiratory risks, and 
its oral cancer risk is probably much lower than that of 
conventional chewed tobacco because snus has a much 
lower nitrosamine content [8,9]. Studies in Sweden, where 
men have used snus for 20 years, have so far failed to detect 
any increase in oral cancer or cardiovascular disease rates 
[5,8,10]. On current evidence the health risks of snus are 
comparable to those of regular alcohol use rather than 
cigarette smoking.
Impact on Tobacco Use by Youth
Many critics are understandably concerned that the tobacco 
industry will use snus to promote nicotine use among 
adolescents and young adults. This is a possibility that 
should be addressed by tighter regulation of all existing 
tobacco products [3]. For example, snus (and other tobacco 
products, including cigarettes) could be made less desirable 
to new users by: prohibiting fl avouring additives, regulating 
packaging and labelling (e.g., generic packaging), and 
prohibiting all tobacco advertising.
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Aggregate Effects on Public Health
Critics of snus argue that its promotion may reduce overall 
tobacco-related disease in current smokers at the cost of 
increasing tobacco use in the population. Whether snus 
produces net aggregate harm or benefi t will depend on who 
in the population uses it. If its use is confi ned to current 
smokers (who would not have otherwise quit tobacco), then 
snus would clearly produce a net benefi t, as it appears to have 
done in Sweden.
Snus would produce net harm only if: (1) it had no effect 
on current rates of smoking; and (2) it was used in the vast 
majority of cases by non-smokers and former smokers [11]. 
Neither case has been observed in Sweden, where smoking 
prevalence has declined because most snus users were 
formerly smokers [12]. Moreover, substantial health gains 
have been achieved in the face of a relatively high prevalence 
of snus use (21% of men are daily snus users). The Swedish 
population prevalence of tobacco use has remained relatively 
steady at around 40% but the proportion of users who smoke 
has gradually declined, with snus now accounting for 58% of 
daily tobacco use [13]. Despite this high prevalence of snus 
use, tobacco-related mortality in Sweden is among the lowest 
in the developed world [14]. If the goal of tobacco control 
is to reduce tobacco-related disease, rather than tobacco use 
per se, then the promotion of snus use by inveterate smokers 
is a promising public health policy.
Effects on Other Tobacco Control Policies
Critics also contend that increased snus use would reduce 
smoking cessation because smokers who would otherwise quit 
due to the inconvenience of smoking bans will use snus when 
smoking is not allowed and smoke when smoking is allowed.
This criticism confuses the primary purpose of smoking 
bans, which is to protect non-smokers from the harmful 
effects of second-hand smoke, with the secondary benefi t 
of increasing smoking cessation. In any case, increased snus 
use in Sweden did not impede smoking cessation efforts. In 
fact, smoking prevalence and tobacco-related mortality have 
both declined in Sweden as snus use has increased. This 
trend appears to be because people who start using snus are 
much less likely to start smoking than those who have never 
used snus, while smokers who start using snus have a higher 
smoking cessation rate than smokers who do not [13].
Public Health Paternalism
Smokers have an ethical right to be accurately informed by 
public health offi cials about THR products. It is paternalistic 
to deny smokers this information for fear that population 
nicotine use may increase. As Kozlowski [15] has argued, 
informing smokers about THR is an effective public health 
measure that properly respects their autonomy. The failure 
to do so, or worse, the dissemination of misinformation that 
snus and smoked tobacco are equally harmful, is untruthful 
and risks creating public mistrust of health messages about 
tobacco use [16,17].
Conclusion
Tobacco smokers who switch to snus will reduce the risks of 
their tobacco use. Based on the Swedish experience, there 
is a strong prima facie case on public health and ethical 
grounds for recommending snus to inveterate smokers who 
want to reduce their health risks and for considering public 
policies (such as lower taxes for snus and public information 
campaigns) to promote its use by smokers. The legitimate 
concerns of THR opponents will be addressed by better 
regulation of all tobacco products rather than either bans on 
snus (as in Europe and Australia) or misinformation about the 
health risks of snus (as in the US where its sale is legal). Public 
health and tobacco control professionals should accordingly 
work for better regulations to make all tobacco products less 
attractive to new (and existing) users rather than attempting 
to discourage smokers from switching to snus through 
misleading claims that snus use is as risky as cigarette smoking.
Simon Chapman and Becky Freeman’s 
Viewpoint: There Are Five Reasons to Be 
Cautious about Snus
The Swedish snus experience deserves the close attention of 
all concerned with reducing the burden of disease caused by 
tobacco use. There has been much acrimony in the debate 
about the international implications of Sweden’s dramatic 
reduction of its burden of disease caused by tobacco. This 
acrimony refl ects clashes of differing ideological values 
aroused by the harm reduction principle. Harm reduction’s 
core principle is that risk reduction strategies can complement 
risk elimination (i.e., cessation) strategies in reducing the 
net harm from tobacco use in populations. This principle is 
heretical to absolutists intolerant of any form of tobacco use.
Reviews of the Swedish experience have raised few doubts 
that its unprecedented decline in tobacco-caused mortality is 
associated with the rise of snus use at the expense of smoking 
[3,8]. Smokers have switched to snus and cohorts of young 
people who would have likely taken up smoking have instead 
adopted snus [18,19]. Signifi cant numbers also use snus as a 
means of stopping tobacco use altogether [13]. 
But unbridled enthusiasts for the Swedish experience 
to be disseminated globally nonetheless face fi ve 
challenging questions: (1) Is Sweden’s snus experience 
shaped by culturally specifi c factors that may not transfer 
to other nations? (2) How would the benefi ts of snus be 
communicated to potential users, and would tobacco 
companies use snus advertising to subvert global advertising 
bans? (3) Because the tobacco industry aims to promote dual 
use (smoking and snus), how do snus enthusiasts defend 
against arguments that such use would increase rather than 
decrease harm? (4) What is the marginal cost utility of the 
tobacco control community putting its effort into informing 
the public about snus compared with the gains to be made 
by continuing “orthodox” tobacco control? (5) Why is the 
public health community’s energy currently being invested 
in supporting tobacco company efforts to freely market snus, 
instead of putting this energy into efforts to promote high 
yielding pharmaceutical “clean” nicotine? 
Culturally Unique? 
While there are legislative barriers to the sale of snus in 
Europe, Australia, New Zealand, and several other nations, 
none exist in most nations. Why then has snus failed to take 
off elsewhere in the way it has taken off in Sweden? Global 
marketing has seen formerly culturally unique products and 
practices succeed internationally, but many fail. Snus users 
typically hold a pinch of loose snus or a snus “portion” in 
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their mouths for around 13–15 hours a day. This is hardly 
a minor, occasional behaviour but one requiring a major 
commitment. Smokeless tobacco sales are growing in the 
US [20] but seemingly nowhere else. Smokeless tobacco has 
failed to become established in any nation other than those 
with long-standing cultural traditions of use. This failure 
suggests widespread smokeless tobacco use is culture-bound 
and highly resistant to migration. 
Communicating Benefi ts
There would be little point in making snus available if its 
benefi ts could not be actively communicated to potential 
users. Tobacco companies face a global shut-down of 
advertising and promotion under the Framework Convention 
on Tobacco Control and have already begun using harm 
reduction to argue for the retention of advertising [21]. 
Given the tobacco industry’s long history of mendacity, we 
can be certain that snus advertising will be used for the wider 
benefi t of the industry. For as long as both cigarettes and 
smokeless products are marketed by the same companies, 
collateral benefi ts to be obtained from riding the harm 
reduction moral imperative (such as dual use—see below) 
will be foremost in cynical industry plans.
Dual Use
Snus enthusiasts in the public health community focus on the 
potential of snus to take people away from smoking. However, 
transnational tobacco companies are already marketing snus 
using slogans that mention smoking, such as: “When you 
can’t smoke, snus”. Here, there is no suggestion of stopping 
smoking, but of use of both cigarettes and snus. Smoking bans 
driven by the evidence on second-hand smoke have caused 
wholesale smoking cessation and reduced cigarette use [22]. 
The tobacco industry is desperate to stem this loss of tobacco 
sales. Promoting dual cigarette/snus use is therefore harm 
increasing, not reducing. Forecasts of increased snus use leading 
to reduced smoking in populations therefore need adjusting to 
incorporate tobacco industry efforts to promote dual use. 
How Much Effort Should We Put into Harm Reduction? 
In nations with robust, comprehensive tobacco control 
programs, smoking rates continue to fall, with weak evidence 
for “hardening” of the smoking population. (“Hardening” 
means that the remaining smokers are mostly “hard core”, 
heavily addicted smokers who are unwilling or unable to quit 
[23].) In fact, there is often a “softening” effect with quit 
rates remaining high and daily smoking frequency reducing 
[24]. In Canada, only 13.4% of the population now smokes 
daily, with another 4.2% smoking less than daily [25]. Youth 
smoking rates are at an historic low in Australia [26]. Tobacco 
control operates on limited budgets and resources. How 
much of these resources should be quarantined to promote 
snus, given that companies could not be trusted to do it? We 
need cost–benefi t comparisons to compare the effects of 
orthodox tobacco control with the effects of promoting snus.
High-Dose “Clean” Nicotine
Real world use of current generation pharmaceutical nicotine 
(nicotine replacement therapy) has not lived up to the 
promise of many clinical trials [27]. Limited but promising 
evidence now available suggests that high-dose pharmaceutical 
nicotine is more effective in reducing smoking [28]. High-
dose pharmaceutical nicotine would not be marketed by 
tobacco companies. Instead, it would be subject to regulatory 
control that would prevent the dual-use promotional 
abuses discussed above through under-the-counter sales at 
pharmacies. Again, issues of cultural transferability apply. 
Would smokers view use of high-dose nicotine replacement 
therapy as an acceptable substitute for the social rituals of 
smoking? The relative lack of advocacy for potent “clean” 
nicotine delivery is intriguing and is rumoured to have much 
to do with internal pharmaceutical industry concern about 
nicotine being less benign than previously thought. Nicotine’s 
role in apoptosis is a fertile area for further research. The 
possible health effects of nicotine must surely be considered 
in any proposal that would encourage widespread use of snus, 
which delivers signifi cant levels of nicotine [29]. 
Coral Gartner and Wayne Hall’s Response 
to Simon Chapman and Becky Freedman’s 
Viewpoint
The health community should beware of over-estimating the 
potential public health impact of snus. Snus use may not fully 
replace cigarette smoking but it may hasten its demise, and 
that would be a substantial public health gain. 
In Australia, a growing smokeless tobacco market was 
curtailed by government bans in the 1980s following 
increased uptake in response to promotional activities 
[30]. This growing market indicates that some Australian 
smokers were willing to try smokeless tobacco. Bans on sales 
of smokeless tobacco products in Australia and Europe are 
a major impediment to fi nding out if snus use is a culture-
bound practice and whether bans are justifi ed. 
Promotion of snus does not preclude the promotion of 
other high-dose, “cleaner” nicotine products. Indeed, we 
would support steps to make both more available. In most 
countries, the only clean forms of nicotine available are low-
dose medicinal replacement products that are unattractive to 
social users. Unfortunately, higher-dose recreational nicotine 
products will encounter substantial diffi culties in gaining 
access to new markets because of irrational regulation that is 
more stringent for pharmaceutical nicotine and snus than for 
smoked tobacco. As a recreational tobacco product, snus may 
seem to smokers like a more natural substitute for cigarettes 
than clean nicotine preparations.
Diversion of funding and human resources from other 
tobacco control strategies to snus promotion is certainly 
a concern. But so too is the effort invested by some in the 
tobacco control community to actively opposing snus use and 
misleadingly claiming that snus use is as harmful as tobacco 
smoking. This energy could be better invested in arguing for 
better regulation of all tobacco products and for lower taxes 
on snus and clean nicotine products to enable them to more 
successfully compete with cigarettes among current tobacco 
users. 
Simon Chapman and Becky Freeman’s Response 
to Coral Gartner and Wayne Hall’s Viewpoint
Gartner and Hall speak of the virtues of inveterate smokers 
switching to snus, implying that there is an intransigent 
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hard core of smokers. The tobacco industry also routinely 
suggests the existence of such a “hard core”. Yet the size of 
this group is constantly shrinking. Quit rates in nations with 
comprehensive tobacco control programs are accelerating, 
and not declining. So whose interests will be served by 
diverting potential quitters into snus, particularly when 
tobacco marketing is already explicitly using snus promotion 
to promote cigarettes? 
We grant that indoor smoking bans were premised on 
reducing harm to non-smokers. But such bans have had 
enormous collateral benefi ts for smokers themselves, by 
stimulating them to quit. Indeed smoking bans have been 
widely appreciated by a large majority of smokers. The 
industry’s “dual use” ambitions—that is, using snus to 
promote cigarettes—could destroy much of these collateral 
benefi ts. Again, whose interests would be served by subverting 
the benefi cial effect of smoking bans? 
We note that Gartner and Hall call for a regulatory scheme 
to safeguard against the snus industry from appealing 
specifi cally to teens by using fl avouring, alluring packaging, 
and teen marketing. But such schemes may take decades 
to implement, particularly when industry is likely to resist 
such regulations. While these are being negotiated, smoking 
prevalence will continue to fall. In nations with high smoking 
prevalence, the argument for snus is more compelling, but 
there is nothing preventing it being marketed now in, for 
example, China. Yet smokeless tobacco has never taken off in 
any nation without a smokeless cultural tradition. 
So we reiterate: smokeless tobacco has low appeal for the 
overwhelming majority of the world’s smokers. There are 
profound risks in letting tobacco industry tigers off their 
leash to use snus to subvert the hard-won provisions of the 
Framework Convention on Tobacco Control—provisions 
that include a ban on all tobacco advertising. Such a ban has 
already been achieved in some nations, but not in the US, 
from where much of the enthusiasm for snus now comes. 
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